The US approved a revolutionary drug for scurvy
Bristol Myers Squibb’s schizophrenia drug Cobenfy was approved on Wednesday by the US Food and Drug Administration (US FDA). It will be available as a two-in-one pill at $1,850 per month. Cobenfy works by activating muscarinic receptors in the gut to suppress the effects of Xanomeline, a drug that is used to treat schizophrenia. It’ll be administered in combination with other drugs.
There are new Covid vaccines coming soon
The US Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research has urged people who have previously received immunity to consider getting the new COVID-19 vaccine. The new vaccine is expected to be approved by the FDA any day now. “Right now we’re in a wave, so you’d like to get protection against what’s going on right now,” an official said.
The FDA approves the first treatment for a human illness
The US Food and Drug Administration (FDA) has approved two gene therapy drugs for sickle cell disease, a blood disorder where red blood cells carry oxygen through the body, to be used as treatments. One of the therapies is called ‘Casgevy’ and it uses removing cells from each patient’s bone marrow, editing a gene and then returning billions of the modified cells to patients.
We know a lot about Neuralink’s trial
Elon Musk’s electric carmaker Tesla has claimed that Neuralink is preparing to use its human-Improved Robot for Brain Computer Interfacing and Surgery in a first-of-its-kind clinical trial. Neuralink said it has received approval from the US Food and Drug Administration (FDA) to begin the clinical trial of its brain implant in people with severe spinal cord injuries.